3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
4
Unknown
1
Terminated
1
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Prostatic Neoplasms
3
Leukemia
3
Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Immunologic Deficiency Syndromes
2
Graft vs Host Disease
2
Fatigue
2
Breast Neoplasms
2
Brain Neoplasms
2
Blast Crisis
2
Waldenstrom Macroglobulinemia
1
Stage IA Uterine Sarcoma
1
Spinal Cord Neoplasms
1
Spinal Cord Compression
1
Sezary Syndrome
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pleural Effusion, Malignant
1
Paranasal Sinus Neoplasms
1
Oligodendroglioma
1
Neurologic Manifestations
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Interventions
pembrolizumab
29
Capecitabine
24
Bevacizumab
23
Cyclophosphamide
22
Gemcitabine
21
Paclitaxel
20
Nivolumab
19
Fluorouracil
19
Docetaxel
18
aldesleukin
17
Leucovorin
17
Irinotecan
17
Oxaliplatin
15
Interleukin-2
14
Radiosurgery
13
Cisplatin
13
Cetuximab
13
fludarabine
12
Carboplatin
12
Albumin-Bound Paclitaxel
11
fludarabine phosphate
10
Ipilimumab
10
Drug Therapy
10
Doxorubicin
10
Sunitinib
9
Radiotherapy
9
Everolimus
9
130-nm albumin-bound paclitaxel
9
Trastuzumab
8
Temozolomide
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasm Metastasis
×
Therapeutics
×
Clear all
NCT05904236
2025-04-08
ICVB-1042
IconOVir Bio
Phase 1
Terminated
17 enrolled